Clinical Trial Update: 68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT) [NA]

View source ↗

Summary

Clinical trial NCT06349512 is evaluating 68Ga-FAPI-46 PET/CT imaging to predict histological response in triple-negative breast cancer and is currently in the r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• 68Ga-FAPI-46 PET/CT

Snippet

Sponsor: Institut Curie | Conditions: Triple Negative Breast Cancer | NA | Status: RECRUITING